Evidence map›Paper›PMID 31273614›Full record

ArticleMolecular biology reports2019

New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.

Polina Gervas, Boris Klyuch, Evgeny Denisov, Artem Kiselev, Alexey Molokov, Lubov Pisareva, Elena Malinovskaya, Evgeny Choynzonov, Nadezda Cherdyntseva

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Summary ofGenes · 2020
    Pooled it
  3. Breast-Ovarian Hereditary Cancer Syndrome: BeyondCurrent oncology (Toronto, Ont.) · 2026
    Review
  4. Article
  5. Mutations ofGenes · 2023
    Article
  6. Article
  7. Mutational Analysis ofCancer management and research · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Polina GervasCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation. pgervas@yandex.ru.ORCID http://orcid.org/0000-0003-0051-8814
Boris KlyuchSOPHiA GENETICS, Moscow, Russia.
Evgeny DenisovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation.
Artem KiselevAlmazov National Medical Research Centre, St. Petersburg, Russia.
Alexey MolokovTomsk State University, Tomsk, Russia.
Lubov PisarevaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation.
Elena MalinovskayaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation.
Evgeny ChoynzonovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation.
Nadezda CherdyntsevaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 5 Kooperativny Street, Tomsk, 634050, Russian Federation.
Tomsk National Research Medical Center · RUNational Research Tomsk State University · RUFederal Almazov North-West Medical Research Centre · RUResearch Centre for Medical Genetics · RU

Funding

Russian Foundation for Basic Research 18-29-09046
6 · The paper itself

Abstract

To date, there are a limited number of reports on inherited gene mutations associated with breast cancer (BC) among Mongoloid indigenous people in Russia. The present study aimed at identifying the BC-associated genes in 26 Russian Mongoloid BC patients (Buryats, Tuvinians and others). The median age of the patients at the time of breast cancer diagnosis was 41 years (range 25-51 years). Genomic DNA isolated from blood samples was used to prepare libraries using a capture-based target enrichment kit (Hereditary Cancer Solution™, SOPHiA GENETICS, Switzerland) covering 27 genes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 and XRCC2). Next-generation sequencing (NGS) was performed on an Illumina NextSeq 500 System (Illumina, USA). In our study, we found 1 Indel and 11 SNPs that passed filters during variant calling. We identified a highly pathogenic germline rs483353122 (c.8208_8209insAG, p.Leu2737Serfs*2) in the BRCA2 gene in six unrelated Tuvinian Mongol BC patients. We also identified a likely damaging germline rs35352891 in the MUTYH gene (c.1118C>T, p.Ala373Val) in one Buryat Mongol BC patient. Other SNPs were classified as variants of uncertain significance. To the best of our knowledge, this report is the first to describe the highly pathogenic variant in the BRCA2 gene (rs483353122) and the likely damaging germline variant in the MUTYH gene (rs35352891) in Russian Mongoloid BC patients with young-onset and/or bilateral and/or familial BC. Further studies are therefore necessary to evaluate the contributions of novel sequence variants to hereditary BC.

Indexed as

Germ-Line MutationAdultAsian PeopleBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDNA GlycosylasesDNA, NeoplasmEthnicityFemaleGenes, BRCA2Genetic Predisposition to DiseaseGenetic VariationHigh-Throughput Nucleotide SequencingHumansMiddle AgedBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA GlycosylasesDNA, NeoplasmmutY adenine glycosylaseBRCA1/2Breast cancerGermline mutationMongoloid race

Identifiers

PMID31273614
OpenAlexW2955967380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.